Work

Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.9009

Authors: Benjamin J. Solomon, Todd Michael Bauer, Enriqueta Felip, Benjamin Besse, Leonard Philip James, Jill S. Clancy, Karen J. Klamerus, Jean-Francois Martini, Antonello Abbattista, Alice Tsang Shaw

Institutions: Peter MacCallum Cancer Centre, Tennessee Oncology, Vall d'Hebron Institut de Recerca, Institut Gustave Roussy, Fondation Gustave Roussy, Pfizer (United States), Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2641698415

Cites:

Cited by: 89

Related to: 10